Minimal residual disease: The advantages of digital over analog polymerase chain reaction

Leukemia and Lymphoma

Volumn 52, Issue 7, 2011, Pages 1161-1163

  Ross, David M ^a,b,c,e   Branford, Susan ^c,d  

^a Haematology Department   (Australia)

^b FLINDERS UNIVERSITY   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

^d Genetics and Molecular Pathology   (Australia)

^e FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB;

CANCER DIAGNOSIS; CHRONIC MYELOID LEUKEMIA; DIAGNOSTIC ACCURACY; DRUG WITHDRAWAL; GENETIC TRANSCRIPTION; MINIMAL RESIDUAL DISEASE; NOTE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MOLECULAR DIAGNOSTIC TECHNIQUES; NANOTECHNOLOGY; NEOPLASM, RESIDUAL; POLYMERASE CHAIN REACTION;

EID: 79959580988     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.580481     Document Type: Note

References (9)

1. Goh H-G, Lin M, Fukushima T, et al. Sensitive quantitation of minimal residual disease in chronic myeloid leukemia using nanofluidic digital polymerase chain reaction assay. Leuk Lymphoma 2011;52:896-904.
2. Mahon FX, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010;11:1029-1035.
3. Ross DM, Branford S, Seymour JF, et al. Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia 2010;24:1719-1724.
4. Rawer D, Borkhardt A, Wilda M, Kropf S, Kreuder J. Influence of stochastics on quantitative PCR in the detection of minimal residual disease. Leukemia 2003;17: 2527-2528; author reply 2528-2531.
5. Bose S, Deininger M, Gora-Tybor J, Goldman JM, Melo JV. The presence of typical and atypical BCR-ABL fusion genes inleukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood 1998;92:3362-3367. (Pubitemid 28492345)
6. Sobrinho-Simoes M, Wilczek V, Score J, Cross NCP, Apperley JF, Melo JV. In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib. Blood 2010;116: 1329-1335.
7. Mattarucchi E, Spinelli O, Rambaldi A, et al. Molecular monitoring of residual disease in chronic myeloid leukemia by genomic DNA compared with conventional mRNA analysis. J Mol Diagn 2009;11:482-487.
8. Bartley PA, Ross DM, Latham S, et al. Sensitive detection and quantification of minimal residual disease in chronic myeloid leukaemia using nested quantitative PCR for BCR-ABL DNA. Int J Lab Hematol 2010;32:e222-e228.
9. Oehler VG, Qin J, Ramakrishnan R, et al. Absolute quantitative detection of ABL tyrosine kinase domain point mutations in chronic myeloid leukemia using a novel nanofluidic platform and mutation-specific PCR. Leukemia 2008;23:396-399.